Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

• Status: Completed
• Trial end date: 2004-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The objective of this study was to prove the bioequivalence of Exemestane 25 mg tablet under fasted conditions

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Roxane Laboratories
• Treatments: Exemestane

Criteria

Inclusion Criteria:

• No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

• Positive test for HIV, Hepatitis B, or Hepatitis C.

• Treatment with known enzyme altering drugs.

• History of allergic or adverse response to exemestane or any comparable or similar product.